Impact of β <sub>3</sub> ‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder
Use of β<sub>3</sub>-AR agonists was associated with an increased risk of kidney cancer compared with anticholinergics. While these findings suggest a potential association between mirabegron use and kidney cancer, further studies are needed to confirm causality. Clinicians should exercise caution when prescribing mirabegron in patients with risk factors for kidney cancer.
Authors
- Jongchan Kim (ORCID: https://orcid.org/0000-0002-0022-6689)
- Won Sik Jang (ORCID: https://orcid.org/0000-0002-9082-0381)
- Soo Beom Choi (ORCID: https://orcid.org/0000-0003-3892-0630)
- Jee Soo Park (ORCID: https://orcid.org/0000-0001-9976-6599)
- Won Sik Ham (ORCID: https://orcid.org/0000-0003-2246-8838)
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
- The Seoul Institute (KR)
- Sorokdo National Hospital (KR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1111/bju.16771
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea